Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors.


Journal

Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637

Informations de publication

Date de publication:
08 2020
Historique:
received: 31 10 2019
revised: 10 01 2020
accepted: 16 04 2020
pubmed: 24 4 2020
medline: 20 1 2021
entrez: 24 4 2020
Statut: ppublish

Résumé

Prior data have variably implicated the inactivation of the mammalian SWItch/Sucrose Non-Fermentable (mSWI/SNF) complex with increased tumor sensitivity to immune checkpoint inhibitors (ICI). Herein, we examined the association between mSWI/SNF variants and clinical outcomes to ICIs. We correlated somatic loss-of-function (LOF) variants in a predefined set of mSWI/SNF genes (

Identifiants

pubmed: 32321774
pii: 2326-6066.CIR-19-0866
doi: 10.1158/2326-6066.CIR-19-0866
pmc: PMC7415546
mid: NIHMS1587095
doi:

Substances chimiques

ARID1A protein, human 0
ARID1B protein, human 0
ARID2 protein, human 0
Biomarkers, Tumor 0
DNA-Binding Proteins 0
Immune Checkpoint Inhibitors 0
Nuclear Proteins 0
PBRM1 protein, human 0
SMARCB1 Protein 0
SMARCB1 protein, human 0
Transcription Factors 0
SMARCA4 protein, human EC 3.6.1.-
DNA Helicases EC 3.6.4.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1075-1084

Subventions

Organisme : NCI NIH HHS
ID : P50 CA101942
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA234018
Pays : United States

Informations de copyright

©2020 American Association for Cancer Research.

Références

Science. 2018 Feb 16;359(6377):770-775
pubmed: 29301958
Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Clin Cancer Res. 2016 May 15;22(10):2396-404
pubmed: 26671993
Cells. 2019 Jul 04;8(7):
pubmed: 31277418
Lancet Oncol. 2016 Jul;17(7):883-895
pubmed: 27269741
Arch Pathol Lab Med. 2017 Jun;141(6):751-758
pubmed: 28557599
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Science. 2018 Feb 16;359(6377):801-806
pubmed: 29301960
Cell. 2018 Nov 15;175(5):1272-1288.e20
pubmed: 30343899
Nat Med. 2018 Aug;24(8):1143-1150
pubmed: 30038220
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
J Immunother Cancer. 2018 Dec 27;6(1):159
pubmed: 30591082
Lancet Oncol. 2016 Dec;17(12):e542-e551
pubmed: 27924752
Cold Spring Harb Perspect Med. 2016 Aug 01;6(8):
pubmed: 27413115
Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):11426-7
pubmed: 26351682
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
BMC Genet. 2009 Dec 23;10:87
pubmed: 20030838
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Cancer Discov. 2017 Aug;7(8):818-831
pubmed: 28572459
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Nat Genet. 2018 Sep;50(9):1271-1281
pubmed: 30150660
Mod Pathol. 2014 Feb;27(2):255-61
pubmed: 23887303
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Ann Oncol. 2019 Aug 1;30(8):1401-1403
pubmed: 31114851
Lung Cancer. 2017 Aug;110:63-67
pubmed: 28676221
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Hum Pathol. 2014 Aug;45(8):1697-703
pubmed: 24925223
J Immunother Cancer. 2019 Mar 29;7(1):90
pubmed: 30922362
Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):E5189-98
pubmed: 26269570
Nat Med. 2018 Sep;24(9):1449-1458
pubmed: 30013197
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Nat Med. 2018 May;24(5):556-562
pubmed: 29736026
Respir Investig. 2013 Mar;51(1):28-34
pubmed: 23561256
Ann Oncol. 2019 Aug 1;30(8):1311-1320
pubmed: 31086949
Science. 2010 Oct 8;330(6001):228-31
pubmed: 20826764
Nat Cell Biol. 2019 Feb;21(2):152-161
pubmed: 30602726
JCI Insight. 2016 Nov 17;1(19):e87062
pubmed: 27882345
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Nat Med. 2017 Aug 4;23(8):1004
pubmed: 28777785
Genet Med. 2016 Jul;18(7):712-9
pubmed: 26681316
JAMA Oncol. 2019 Jul 25;:
pubmed: 31343665
Cell. 2012 Jul 20;150(2):251-63
pubmed: 22817889
Nat Med. 2018 Dec;24(12):1941
pubmed: 30291359
JAMA Surg. 2019 Jan 1;154(1):74-79
pubmed: 30422256
JAMA Oncol. 2019 Sep 5;:
pubmed: 31486842
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
Nat Med. 2019 Mar;25(3):389-402
pubmed: 30842677
Lung Cancer. 2019 Jun;132:65-71
pubmed: 31097096
Cell. 2012 Sep 14;150(6):1107-20
pubmed: 22980975
J Thorac Oncol. 2018 Aug;13(8):1128-1137
pubmed: 29723688
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
Lancet Oncol. 2018 Nov;19(11):1480-1492
pubmed: 30361170
Nat Genet. 2013 Jun;45(6):592-601
pubmed: 23644491
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
Nat Genet. 2011 Aug 07;43(9):875-8
pubmed: 21822268
Nature. 2011 Jan 27;469(7331):539-42
pubmed: 21248752
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821

Auteurs

Sarah Abou Alaiwi (S)

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Amin H Nassar (AH)

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

Wanling Xie (W)

Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.

Ziad Bakouny (Z)

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Jacob E Berchuck (JE)

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

David A Braun (DA)

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Sylvan C Baca (SC)

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Pier Vitale Nuzzo (PV)

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genoa, Genoa, Italy.

Ronan Flippot (R)

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Medical Oncology, Gustave Roussy, Villejuif, France.

Tarek H Mouhieddine (TH)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Liam F Spurr (LF)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Yvonne Y Li (YY)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Taiwen Li (T)

Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China.

Abdallah Flaifel (A)

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

John A Steinharter (JA)

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Claire A Margolis (CA)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Natalie I Vokes (NI)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Heng Du (H)

Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

Sachet A Shukla (SA)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Andrew D Cherniack (AD)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Guru Sonpavde (G)

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Robert I Haddad (RI)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Mark M Awad (MM)

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Marios Giannakis (M)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

F Stephen Hodi (FS)

Melanoma Center, Dana-Farber Cancer Institute, Boston, Massachusetts.

X Shirley Liu (XS)

Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.

Sabina Signoretti (S)

Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.

Cigall Kadoch (C)

Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.

Matthew L Freedman (ML)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

David J Kwiatkowski (DJ)

Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

Eliezer M Van Allen (EM)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Toni K Choueiri (TK)

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. toni_choueiri@dfci.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH